Vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy.
- Author:
Yi-ran HUANG
1
Author Information
1. Department of Urology, Renji Hospital of Shanghai Second Medical University, Shanghai 200127, China.
- Publication Type:Journal Article
- MeSH:
Double-Blind Method;
Erectile Dysfunction;
drug therapy;
etiology;
Humans;
Imidazoles;
therapeutic use;
Male;
Phosphodiesterase Inhibitors;
therapeutic use;
Piperazines;
therapeutic use;
Postoperative Complications;
drug therapy;
Prostatectomy;
Randomized Controlled Trials as Topic;
Spheroids, Cellular;
Sulfones;
therapeutic use;
Triazines;
therapeutic use;
Vardenafil Dihydrochloride
- From:
National Journal of Andrology
2005;11(1):76-79
- CountryChina
- Language:Chinese
-
Abstract:
More than one-third of men may experience erectile dysfunction (ED) after nerve-sparing radical retropubic prostatectomy. A recent study has shown that vardenafil, a phosphodiesterase 5 inhibitor, could significantly improve the key indices of erectile function in men after unilateral or bilateral nerve-sparing radical retropubic prostatectomy. Few adverse events were observed in the study.
